Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04898153
Other study ID # XEL-CR-08
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date June 10, 2021
Est. completion date September 2027

Study information

Verified date July 2023
Source Xeltis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A feasibility study is to assess the preliminary safety and performance of the Xeltis hemodialysis access (aXess) graft.


Description:

A prospective, single arm, non-randomized FIH feasibility study to evaluate the preliminary safety and performance of the Xeltis hemodialysis access graft in subjects older than 18 years with end-stage renal disease, who plan to undergo hemodialysis for at least the first 6 months after study access creation, and are deemed not suitable for fistula creation by the operating surgeon.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date September 2027
Est. primary completion date March 24, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subjects older than 18 years with end-stage renal disease (ESRD) who are not, or who are no longer, candidates for creation of an autogenous AV fistula, and therefore require placement of an AV graft in the upper extremity to start or maintain hemodialysis therapy - Suitable anatomy for the implantation of an aXess graft - The patient has been informed about the nature of the study, agrees to its provisions, and has provided written informed consent - The patient has been informed and agrees to pre- and post- procedure follow up - Life expectancy of at least 12 months Exclusion Criteria: - History or evidence of severe cardiac disease (NHYA Functional Class IV and/or EF <30%), myocardial infarction within six months of study entry, ventricular tachyarrhythmias requiring continuing treatment, or unstable angina - Stroke within six months before study entry - Active clinically significant autoimmune / inflammatory disease, immunodeficiency (including AIDS / HIV), use of immunosuppressive therapy or medication that likely interferes with restorative therapies - Abnormal blood values (e.g. leurkopenia with white blood cell (WBC) count < 4,000/mm3 and/or anemia with hemoglobin <8g/dL and/or thrombocytopenia < 100,000/mm3) that could influence patient recovery and/or graft hemostasis - Any active local or systemic infection (WBC > 15,000/mm3) - Uncontrolled or poorly controlled diabetes (hemoglovin A1c > 8% despite standard care) or hospitalization for poor glucose control within the previous 6 months - Reduced liver function, defined as: >2x the upper limit of normal for serum bilirubin, aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase; International Normalized Ratio (INR) > 1.5 or prothrombin time (PT) > 18 seconds - Known heparin-induced thrombocytopenia - Active bleeding disorder and/or any coagulopathy or thrombo embolic disease - History or evidence of severe peripheral vascular disease in the upper limbs - Known or suspected central vein obstruction on the side of planned graft implantation - Previous dialysis access graft in the operative limb unless the aXess graft can be placed more proximally than the previous failed graft - More than 1 failed dialysis access graft in the operative limb - Anticipated renal transplant within 6 months - Subjects receiving a forearm graft which crosses the elbow - Allergies to study device (Nitinol) or agents/medication, such as contrast agents, aspirin, or clopidogrel, that cant be controlled medically - Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives - Subject is participating in another study - Previous enrollment in this study - Any other condition which, in the judgement of the investigator would preclude adequate evaluation for the safety and efficacy of the study conduit

Study Design


Related Conditions & MeSH terms


Intervention

Device:
aXess
Patients will be implanted with one Xeltis hemodialysis access device (aXess) in the arm

Locations

Country Name City State
Belgium A.Z. Sint Jan Brugge
Belgium Ziekenhuis Oost-Limburg Genk
Belgium UZ Ghent Ghent
Italy Universita degli studi dell'Insubria Varese
Latvia P. Stradins Clinical University Hospital Riga
Lithuania Vilnius University Hospital Santaros Klinikos Corpus A. Vilnius

Sponsors (1)

Lead Sponsor Collaborator
Xeltis

Countries where clinical trial is conducted

Belgium,  Italy,  Latvia,  Lithuania, 

Outcome

Type Measure Description Time frame Safety issue
Primary Freedom from device related serious adverse events The number of patients who have a device related serious adverse event 6 months
Primary Functional patency of graft The number of patients with a functionally patent graft 6 months
Secondary Freedom from device related serious adverse events The number of patients who have a device related serious adverse event 12, 18, 24, and 60 months
Secondary Functional patency of graft The number of patients with a functionally patent graft 12, 18, 24, and 60 months
Secondary Patency (primary, primary assisted, and secondary) of graft The number of patients with a patient graft 6, 12, 18, 24, and 60 months
Secondary Time to potential central venous catheter removal Time that patients with a central venous catheter could have had the catheter removed after the Xeltis hemodialysis access graft was placed Assessed retrospectively at 30 days
Secondary Time to loss of patency (primary, primary assisted, and secondary) Number of days from implant to graft occlusion in patients who no longer have a patent graft 6, 12, 18, 24, and 60 months
Secondary Rate of access related interventions required to achieve/maintain patency Number of interventions that were performed on grafts to achieve/maintain patency 6, 12, and 24 months
Secondary Rate of access site infections Number of access graft sites that become infected 6, 12, and 24 months
Secondary Proportion of hemodialysis (HD) sessions completed via central venous catheter Number of hemodialysis sessions performed with a central venous catheter vs. the number of sessions performed with the Xeltis hemodialysis access graft 12 months
Secondary Number of days with central venous catheter in place (catheter contact time) Number of days the patients have a central venous catheter in place irrespective of access abandonment 12 months
Secondary Pseudoaneurysm formation Number of grafts that have a pseudoaneurysm form 6, 12, and 24 months
See also
  Status Clinical Trial Phase
Completed NCT04076488 - Feasibility of an Interactive Tablet-based Exercise Program for People With Chronical Diseases N/A
Completed NCT03289650 - Extended Release Tacrolimus vs. Twice-Daily Tacrolimus Phase 3
Completed NCT04042324 - A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients Phase 1/Phase 2
Completed NCT01242904 - Use of a Bimodal Solution for Peritoneal Dialysis Phase 2
Active, not recruiting NCT03183245 - Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis Phase 3
Completed NCT03257410 - Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients N/A
Completed NCT03627299 - Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors Phase 4
Recruiting NCT05917795 - Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates N/A
Terminated NCT03539861 - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients N/A
Withdrawn NCT02130817 - Belatacept in Kidney Transplantation of Moderately Sensitized Patients Phase 4
Completed NCT05540457 - Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis) N/A
Not yet recruiting NCT04900610 - The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis N/A
Recruiting NCT02176434 - Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease N/A
Active, not recruiting NCT02581449 - Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis Phase 2
Completed NCT02832440 - Comparison of Two Exercise Programmes in Patients Undergoing Hemodialysis N/A
Completed NCT02134314 - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI Phase 1/Phase 2
Completed NCT02832466 - Quantifying the Deterioration of Physical Function in Renal Patients N/A
Completed NCT02215655 - Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence N/A
Completed NCT02830490 - Reliability of Functional Measures in Hemodialysis Patient. N/A
Recruiting NCT01912001 - Virtual Ward for Home Dialysis N/A